IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v122y2018i12p1283-1286.html
   My bibliography  Save this article

Underuse of innovative medicines in Germany: A justification for government intervention?

Author

Listed:
  • Gandjour, Afschin

Abstract

The German market for innovative medicines is characterized by simultaneous underuse and overuse. In order to address these deficits and improve decision making by physicians, the German parliament recently passed a law which mandates implementing reimbursement decisions on innovative medicines in the prescription software for physicians. This article discusses the political process leading to the law as well as its rationale in view of economic theory. Based on the considerably larger extent of underuse than overuse of innovative medicines in Germany this article predicts that the law will lead to an increase in sales by the pharmaceutical industry. It argues that legislation to increase prescription rates through information technology is questionable in a market where competitive forces should prevail. The correct approach, in line with economic theory, is either to improve information availability for patients or change existing regulation in the case of government failure. The latter may include revoking penalties for physician prescriptions and imposing prescription exclusions.

Suggested Citation

  • Gandjour, Afschin, 2018. "Underuse of innovative medicines in Germany: A justification for government intervention?," Health Policy, Elsevier, vol. 122(12), pages 1283-1286.
    • Handle: RePEc:eee:hepoli:v:122:y:2018:i:12:p:1283-1286
    DOI: 10.1016/j.healthpol.2018.08.009
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851018304147
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2018.08.009?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:122:y:2018:i:12:p:1283-1286. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.